Health state utility values by cancer stage: a systematic literature review
Autor: | Karen C. Chung, Mir-Masoud Pourrahmat, Mir Sohail Fazeli, Divya Pushkarna, Marg Hux, Anuraag Kansal, Ashley E. Kim |
---|---|
Rok vydání: | 2021 |
Předmět: |
Oncology
medicine.medical_specialty I00 Colorectal cancer Cost-Benefit Analysis Cancer stage Economics Econometrics and Finance (miscellaneous) Health state utility 03 medical and health sciences Breast cancer 0302 clinical medicine Quality of life Neoplasms Internal medicine Humans Medicine 030212 general & internal medicine I10 Stage (cooking) Disutility Lung cancer Cancer Neoplasm Staging Cervical cancer Original Paper business.industry Health Policy Systematic literature review medicine.disease Systematic review 030220 oncology & carcinogenesis Quality of Life business |
Zdroj: | The European Journal of Health Economics |
ISSN: | 1618-7601 1618-7598 |
DOI: | 10.1007/s10198-021-01335-8 |
Popis: | Objectives Cancer diagnoses at later stages are associated with a decrease in health-related quality of life (HRQOL). Health state utility values (HSUVs) reflect preference-based HRQOL and can vary based on cancer type, stage, treatment, and disease progression. Detecting and treating cancer at earlier stages may lead to improved HRQOL, which is important for value assessments. We describe published HSUVs by cancer type and stage. Methods A systematic review was conducted using Embase, MEDLINE®, EconLit, and gray literature to identify studies published from January 1999 to September 2019 that reported HSUVs by cancer type and stage. Disutility values were calculated from differences in reported HSUVs across cancer stages. Results From 13,872 publications, 27 were eligible for evidence synthesis. The most frequent cancer types were breast (n = 9), lung (n = 5), colorectal (n = 4), and cervical cancer (n = 3). Mean HSUVs decreased with increased cancer stage, with consistently lower values seen in stage IV or later-stage cancer across studies (e.g., − 0.74, − 0.44, and − 0.51 for breast, colorectal, and cervical cancer, respectively). Disutility values were highest between later-stage (metastatic or stage IV) cancers compared to earlier-stage (localized or stage I–III) cancers. Conclusions This study provides a summary of HSUVs across different cancer types and stages that can inform economic evaluations. Despite the large variation in HSUVs overall, a consistent decline in HSUVs can be seen in the later stages, including stage IV. These findings indicate substantial impairment on individuals’ quality of life and suggest value in early detection and intervention. |
Databáze: | OpenAIRE |
Externí odkaz: |